FDA Approves Moderna's New COVID-19 Vaccine with Restrictions
TL;DR Summary
The FDA has approved Moderna's new COVID-19 vaccine, mNexspike, which is a lower-dose, potentially refrigerator-stable shot targeting the spike protein, for use in adults 65 and older and high-risk individuals aged 12-64, based on successful phase 3 trial results. The vaccine is expected to be available for the 2025-26 season alongside Spikevax.
- FDA approves Moderna's new COVID-19 vaccine CIDRAP
- The FDA Just Approved a New Covid Vaccine Mother Jones
- FDA grants limited approval to new Covid vaccine from Moderna NBC News
- Another Covid vaccine approval with restrictions attached statnews.com
- How Moderna Went From Pandemic Hero to Vaccine Victim WSJ
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
8 min
vs 8 min read
Condensed
97%
1,564 → 52 words
Want the full story? Read the original article
Read on CIDRAP